专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06489354B1 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity 失效
标题翻译： 3-烷基取代的吡咯烷调节剂的趋化因子受体活性
公开(公告)号：US06489354B1
公开(公告)日：2002-12-03
申请号：US09516771
申请日：2000-03-01
申请人： Jianming Bao , Robert K. Baker , William H. Parsons , Kathleen Rupprecht
发明人： Jianming Bao , Robert K. Baker , William H. Parsons , Kathleen Rupprecht
IPC分类号： A61K3140
CPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14
摘要： The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
摘要翻译：本发明涉及可用作趋化因子受体活性调节剂的式I的吡咯烷化合物（其中R1，R2，R3，R4c，R4d和R4f如本文所定义）。特别地，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。

2. 发明授权

US06362201B1 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity 失效
标题翻译： 3-环丙基和3-环丁基吡咯烷调节剂的趋化因子受体活性
公开(公告)号：US06362201B1
公开(公告)日：2002-03-26
申请号：US09516775
申请日：2000-03-01
申请人： Robert K. Baker , William H. Parsons , Kathleen Rupprecht
发明人： Robert K. Baker , William H. Parsons , Kathleen Rupprecht
IPC分类号： A61K31445
CPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , Y10S514/922
摘要： The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
摘要翻译：本发明涉及可用作趋化因子受体活性调节剂的式I的吡咯烷化合物（其中R1，R2，R3，R4c，R4d和R4f如本文所定义）。特别地，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。

3. 发明授权

US06372764B1 Pyrrolidine modulators of chemokine receptor activity 失效
标题翻译：趋化因子受体活性的吡咯烷调节剂
公开(公告)号：US06372764B1
公开(公告)日：2002-04-16
申请号：US09516754
申请日：2000-03-01
申请人： Jianming Bao , Robert K. Baker , William H. Parsons , Kathleen Rupprecht
发明人： Jianming Bao , Robert K. Baker , William H. Parsons , Kathleen Rupprecht
IPC分类号： A61K31445
CPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14
摘要： The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
摘要翻译：本发明涉及可用作趋化因子受体活性调节剂的式I的吡咯烷化合物（其中R1，R2，R3，R4c，R4d和R4f如本文所定义）。特别地，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。

4. 发明授权

US5670504A 2,6-diaryl pyridazinones with immunosuppressant activity 失效
标题翻译：具有免疫抑制活性的2,6-二芳基哒嗪酮
公开(公告)号：US5670504A
公开(公告)日：1997-09-23
申请号：US392588
申请日：1995-02-23
申请人： Richard J. Bochis , Andrew Kotliar , William H. Parsons , Kathleen Rupprecht
发明人： Richard J. Bochis , Andrew Kotliar , William H. Parsons , Kathleen Rupprecht
IPC分类号： C07D237/18 , A61K31/435 , A61K31/50 , A61K31/52 , A61K31/535 , A61K31/70 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/02 , A61P1/16 , A61P9/00 , A61P11/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P27/02 , A61P29/00 , A61P31/12 , A61P37/06 , A61P43/00 , C07D237/24
CPC分类号： C07D237/24
摘要： A class of 2,6-diarylpyridazinones of general structural formula I have been identified that exhibit exhibit immunosuppressant activity with human T-lymphocytes, and are useful as an immunosuppressants. ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof
摘要翻译：已经鉴定了一类具有结构式I的2,6-二芳基哒嗪酮，其表现出与人T淋巴细胞具有免疫抑制活性，并且可用作免疫抑制剂。 I或其药学上可接受的盐，水合物或晶体形式

5. 发明授权

US06303593B1 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity 失效
标题翻译：趋化因子受体活性的3-噻吩基和3-呋喃基吡咯烷调节剂
公开(公告)号：US06303593B1
公开(公告)日：2001-10-16
申请号：US09516621
申请日：2000-03-01
申请人： Jianming Bao , Christopher Forbes , Shouwu Miao , William H. Parsons , Kathleen Rupprecht , Frank Kayser
发明人： Jianming Bao , Christopher Forbes , Shouwu Miao , William H. Parsons , Kathleen Rupprecht , Frank Kayser
IPC分类号： A61K31395
CPC分类号： C07D409/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/04
摘要： The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
摘要翻译：本发明涉及可用作趋化因子受体活性调节剂的式I的吡咯烷化合物（其中R1，R2，R3，R4c，R4d和R4f如本文所定义）。特别地，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。

6. 发明授权

US5284840A Alkylidene macrolides having immunosuppressive activity 失效
标题翻译：具有免疫抑制活性的亚烷基大环内酯类
公开(公告)号：US5284840A
公开(公告)日：1994-02-08
申请号：US897738
申请日：1992-06-12
申请人： Kathleen Rupprecht , Robert Baker
发明人： Kathleen Rupprecht , Robert Baker
IPC分类号： C07D498/18 , A61K31/395 , C07D267/00
CPC分类号： C07D498/18
摘要： Alkylidene macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by derivitization at C-9 or C-22. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma; as hair revitalizing agents, especially in the treatment of male pattern alopecia oralopecia senilis; in the reversal of multidrug resistance of tumor cells; in treatment of inflammation of mucosa and blood vessels, gastric ulcers, vascular damage, ischemic bowel disease, inflammatory bowel disease, necrotizing entercolitis, intestinal lesions associated with thermal burns; in the treatment of cytomegalovirus infection; and in the treatment of idiopathic thrombocytopenic purpura and Basedow's disease.
摘要翻译：通过在C-9或C-22衍生化，从合适的前体制备通式结构式I的亚烷基大环内酯：这些大环内酯类免疫抑制剂可用于哺乳动物宿主用于治疗自身免疫性疾病，感染性疾病和/或预防外来器官移植排斥反应。此外，这些大环内酯类免疫抑制剂可用于局部治疗炎性和过度增生性皮肤病以及免疫介导疾病的皮肤表现。此外，这些大环内酯可用于治疗可逆性阻塞性气道疾病，特别是哮喘; 作为头发活化剂，特别是在治疗男性脱发性秃发症的过程中，在逆转肿瘤细胞的多药耐药性; 治疗粘膜和血管炎症，胃溃疡，血管损伤，缺血性肠病，炎性肠病，坏死性肠炎，与热灼伤相关的肠道损伤; 在治疗巨细胞病毒感染; 并在治疗特发性血小板减少性紫癜和基诺病。

7. 发明申请

US20070123505A1 Heterocycle-substituted 3-alkyl azetidine derivatives 失效
标题翻译：杂环取代的3-烷基氮杂环丁烷衍生物
公开(公告)号：US20070123505A1
公开(公告)日：2007-05-31
申请号：US11602577
申请日：2006-11-21
申请人： Robert Baker , Jeffrey Hale , Shouwu Miao , Kathleen Rupprecht
发明人： Robert Baker , Jeffrey Hale , Shouwu Miao , Kathleen Rupprecht
IPC分类号： A61K31/506 , A61K31/501 , A61K31/497 , A61K31/4439 , A61K31/427 , A61K31/4178 , C07D403/02 , A61K31/397
CPC分类号： C07D257/04 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/113 , C07D403/10 , C07D413/10 , C07D417/04 , C07D417/06 , C07D417/14
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ）和非酒精性脂肪性肝炎（NASH）。

8. 发明申请

US20060293299A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives 失效
公开(公告)号：US20060293299A1
公开(公告)日：2006-12-28
申请号：US10557246
申请日：2004-06-09
申请人： Robert Baker , Jianming Bao , Shouwu Miao , Kathleen Rupprecht
发明人： Robert Baker , Jianming Bao , Shouwu Miao , Kathleen Rupprecht
IPC分类号： A61K31/4439 , A61K31/4178 , A61K31/397 , C07D403/02 , C07D409/02
CPC分类号： C07D205/04 , C07D205/06 , C07D401/06 , C07D403/06 , C07D403/10 , C07D405/06 , C07D409/06
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

9. 发明授权

US4999436A Aryl-substituted thiophene 3-ols, derivatives and analogs useful as lipoxgenase inhibitors 失效
标题翻译：芳基取代的噻吩3-ols，可用作脂氧合酶抑制剂的衍生物和类似物
公开(公告)号：US4999436A
公开(公告)日：1991-03-12
申请号：US397325
申请日：1989-08-22
申请人： Bruce E. Witzel , Debra L. Allison , Charles G. Caldwell , Kathleen Rupprecht
发明人： Bruce E. Witzel , Debra L. Allison , Charles G. Caldwell , Kathleen Rupprecht
IPC分类号： C07D333/32 , C07D333/50 , C07D333/64 , C07D333/78 , C07D333/80 , C07D409/04
CPC分类号： C07D409/04 , C07D333/32 , C07D333/50 , C07D333/64 , C07D333/78 , C07D333/80
摘要： Aryl substituted thiophenes 3-ols, its dihydro derivatives, 1-oxide and 1,1-dioxide analogs, as well as aryl substituted furans, are 5-lipoxygenase inhibitors useful in the treatment of inflammation and other leukotriene-mediated diseases.
摘要翻译：芳基取代的噻吩3-ols，其二氢衍生物，1-氧化物和1,1-二氧化物类似物以及芳基取代的呋喃是可用于治疗炎症和其它白三烯介导的疾病的5-脂氧合酶抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式